Dr. Swaminathan is an aspiring immunologist dedicated to bridging the gap between fundamental research and clinical application. She currently serves as a Postdoctoral Scholar at the University of California, San Francisco, where she joined the Prahl Lab in 2024. Her postdoctoral work is centered on pioneering new analytical methods to dissect the complexities of the pediatric immune system. By investigating immune responses to key childhood vaccines like those for COVID-19 and RSV, she aims to provide critical insights that will inform the development of next-generation vaccines for the world's youngest and most vulnerable populations.

Dr. Swaminathan’s expertise is built on a foundation of high-impact doctoral research. While earning her PhD in Immunology from The University of Queensland at the QIMR Berghofer Medical Research Institute, she contributed to a project that culminated in a remarkable achievement: the design and preclinical validation of an allogeneic T-cell therapy for treating severe SARS-CoV-2 infections in immunocompromised individuals.

With a unique background that spans academic research and industry standards, including experience in GLP and GMP-compliant environments, Dr. Swaminathan possesses a robust technical skillset in T cell therapy development, flow cytometry, and virology. Her work is driven by a commitment to leveraging the power of immunology to create tangible solutions for global health challenges.